Abstract
The myeloproliferative neoplasms (MPNs) are a group of leukemias that result from clonal expansion of one or more myeloid lineage cells. This clonal expansion is due to mutant tyrosine kinases or mutated downstream proteins. The related molecular drivers cause overlapping pathological, laboratory, and clinical presentations. Some MPNs share oncogenic driver mutations, while others are defined by specific translocations. The accurate diagnosis has prognostic and therapeutic implications and requires close correlation with pathological, clinical, and laboratory data. Most MPNs are initially indolent with effective hematopoiesis early in the course of disease; however, they typically progress to an acute leukemia, a marrow failure due to myelofibrosis, or a myelodysplastic syndrome. This leads to a wide variation of morphologic appearances for the pathologist depending on when in the patient’s natural course of disease the sample crosses the microscope stage.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. (revised 4th edition). Lyon: IARC; 2017.
Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms. JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–38.
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1381–90.
Tefferi A, Elliott M, Pardanani A. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol. 2015;22:171–6.
Ismail SI, Naffa RG, Yousef AF, Ghanim MT. Incidence of bcr-abl fusion transcripts in healthy individuals. Mol Med Rep. 2014;9(4):1271–76
Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematol. 2014;99(9):1448–55.
Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693–703.
Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017;10(5):459–77.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–14.
Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123(23):3574–7.
Alvarez-Twose I, Matito A, Morgado JM, Sánchez-Muñoz L, Jara-Acevedo M, García-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17. Oncotarget. 2017;8(40):68950–63.
Zhou A, Afzal A, Oh ST. Prognostication in Philadelphia chromosome negative myeloproliferative neoplasms: a review of the recent literature. Curr Hematol Malig Rep. 2017;12(5):397–405.
Reiter A, Gotlib A. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704–14.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis. Clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–7.
Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria, and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25.
Boyer DF. Blood and bone marrow evaluation for eosinophilia. Arch Pathol Lab Med. 2016;140:1060–7.
Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndromes with features similar to chronic eosinophilic syndrome, not otherwise specified. Mod Pathol. 2016;29:854–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Keeney, M.E., Bhagavathi, S. (2020). Chronic Myeloproliferative Neoplasms (Other Than Chronic Myeloid Leukemia). In: Wang, E., Lagoo, A.S. (eds) Practical Lymph Node and Bone Marrow Pathology. Practical Anatomic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-32189-5_23
Download citation
DOI: https://doi.org/10.1007/978-3-030-32189-5_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32188-8
Online ISBN: 978-3-030-32189-5
eBook Packages: MedicineMedicine (R0)